IMTX - Rasio utang marang kapitalisasi buku Immatics N.V.

Logo korporat perusahaan Immatics (IMTX)

Immatics N.V. (IMTX) is developing T-cell oncology therapies, positioning itself as a future pricing power leader in the absence of comparable alternatives. The strategy is based on deep R&D and alliances with pharmaceutical behemoths without pursuing mergers. The infrastructure relies on German laboratories and its own manufacturing plant in the US. This chart reflects the current share price on GURU.Markets at 0.04, demonstrating the market valuation of this innovative business.

IMTX Immatics N.V.: Rasio utang marang kapitalisasi buku ing interval 04.07.2022 - 27.10.2026

Ringkesan rincian data analitis Immatics NV (IMTX)

- rega lan prakiraan konsensus rega:
Rega saham Immatics N.V.|IMTX - Target konsensus
- data kapitalisasi pasar:
Nilai pasar Immatics Biotechnologies|IMTX - Total Nilai Perusahaan
- data kapitalisasi buku:
Aset Bersih saben Siji Saham Immatics|IMTX - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku immatics.com|IMTX - Aset Perusahaan
- data utang lan likuiditas:
Total Utang marang Modal Immatics N.V.|IMTX - Tanggungan utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Immatics Corp|IMTX - Utang kumulatif perusahaan|Utang marang nilai buku Immatics Biotechnologies
Analisis kabeh metrik perusahaan:IMTX, Immatics N.V.
Produk dadi Immatics Biotechnologies

This indicator determines the degree of capital structure dependence on borrowed funds by comparing total debt obligations to the book value of equity. Analyzing the debt-to-capitalization ratio allows for an assessment of the financial stability of Immatics N.V. (IMTX), whose high profitability is supported by flawless cold chain logistics during the transportation of complex immuno-oncology drugs.

Pesaing Immatics N.V.

ImmunityBio, Inc. - Utang-utang marang kapitalisasi buku|immunocore.com - Utang marang nilai buku|JANX (Janux Therapeutics, Inc.) - Rasio utang marang kapitalisasi buku|RCUS: Utang-utang marang nilai buku|Zymeworks Corp (ZYME) - Rasio utang marang kapitalisasi buku|TNGX (Tango Therapeutics Corp) - Rasio utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku IOVA (Iovance Biotherapeutics)|Utang-utang marang nilai buku xencor.com|CMPX: Utang-utang marang kapitalisasi buku|Utang marang aset resik Replimune Group Inc REPL|LYEL: Utang marang nilai buku|IPHA - Utang-utang marang nilai buku|Utang marang nilai buku Pyxis (PYXS)|CGEN - Rasio utang marang aset resik|IO Biotech - Utang-utang marang kapitalisasi buku|STRO (Sutro Biopharma Inc.) - Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku INKT|Utang marang nilai buku HOWL|Rasio utang marang kapitalisasi buku IMMX (Immix Biopharma, Inc.)|Utang marang nilai buku ALX Oncology Holdings Inc. ALXO|Utang marang nilai buku CUE (Cue Biopharma, Inc.)|PDS Biotech - Utang-utang marang kapitalisasi buku|Sonnet BioTherapeutics Holdings Inc. (SONN) - Rasio utang marang kapitalisasi buku|MAIA: Rasio utang marang nilai buku|Rasio utang marang kapitalisasi buku LIMN|Utang-utang marang nilai buku LAVA Therapeutics|NextCure - Utang marang nilai buku|Utang marang aset resik Leap Tx (LPTX)|Utang marang nilai buku Intensity Therapeutics|Utang marang modal buku senseibio.com (SNSE)|Utang-utang marang kapitalisasi buku Theriva Biologics, Inc.|Rasio utang marang aset resik Gritstone bio Inc. GRTS|KA (Kineta) - Utang-utang marang kapitalisasi buku|NEXI: Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku turnstonebio.com TSBX|Vaccinex Inc (VCNX) - Rasio utang marang aset resik|HARP (Harpoon Therapeutics) - Utang-utang marang kapitalisasi buku